Pharmaceutical News

RSS

Personalised medicine could help develop effective treatments for serious diseases

Personalised medicine is a field that holds a lot of promise as a provider of practices and technology that could help develop more effective treatments for serious diseases such as cancer. Personalised medicine involves tailoring treatment according to the genetic profile and molecular makeup of each patient.

19 Nov 2010

Doctors recommend drug holidays from bisphosphonates to enhance bone health

Taking time off from certain osteoporosis drugs may be beneficial to bone health, according to a study conducted at Loyola University Health System. Researchers found that bone density remained stable for three years in patients who took a drug holiday from bisphosphonates, a popular class of osteoporosis drugs that can cause fractures in the thigh bones and tissue decay in the jaw bone.

19 Nov 2010

Jeffrey Bethune files lawsuit against Bristol-Myers Squibb for denying overtime pay

Former pharmaceutical representative Jeffrey Bethune today filed a lawsuit in federal court in Manhattan against Bristol-Myers Squibb Company (BMS), charging the giant drug corporation with illegally denying him compensation for overtime hours.

19 Nov 2010

National monitoring essential for preventing emergence of malaria drug resistance

WHO is calling on countries to be increasingly vigilant in monitoring antimalarial drug efficacy in order to allow for early detection of artemisinin resistance.1 This is one among several conclusions of the Global report on antimalarial drug efficacy and drug resistance: 2000-2010, released today. The report is based on 1100 studies conducted by national malaria control programs and research institutes over the ten-year period.

19 Nov 2010

Advanced Life Sciences submits application to FDA for ALS-886 to treat ARDS

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced that the Company has applied to the U.S. Food and Drug Administration for orphan drug designation for ALS-886, a novel therapy to reduce and prevent tissue damage, for the treatment of Acute Respiratory Distress Syndrome (ARDS).

19 Nov 2010

Ethicon submits BLA to FDA for Fibrin Pad

Ethicon, Inc., a worldwide leader in surgical care, announced today that the company has submitted a Biologic License Application (BLA) to the U.S. Food and Drug Administration (FDA) for the Fibrin Pad, a novel product candidate that combines Ethicon's biomaterials and plasma-derived biologics (Human Fibrinogen and Human Thrombin), to aid in stopping soft tissue bleeding during surgery.

19 Nov 2010

FDA approves IDE application for Home Hemodialysis system

Baxter International Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) application for a Home Hemodialysis (HD) system in development through a collaboration between DEKA Research and Development Corp., HHD LLC, and Baxter.

From Baxter International Inc. 19 Nov 2010

FDA approves new drug application for NEXTERONE Premixed Injection

Prism Pharmaceuticals, Inc. announced today that the U.S. Food & Drug Administration has approved the supplemental new drug application for NEXTERONE (amiodarone HCl) Premixed Injection, the first and only premixed intravenous (IV) bag formulation of the antiarrhythmic agent amiodarone IV.

19 Nov 2010

Expert panel to endorse newly approved therapeutic vaccine for advanced prostate cancer

Provenge is one step closer to being covered by Medicare. An expert panel voted Wednesday to endorse the newly approved therapeutic vaccine for men with advanced prostate cancer.

19 Nov 2010

New findings show promising treatment for MS

Successfully treating and reversing the effects of multiple sclerosis, or MS, may one day be possible using a drug originally developed to treat chronic pain, according to Distinguished Professor Linda Watkins of the University of Colorado at Boulder.

19 Nov 2010

Eisai signs statement of intent with WHO to supply medicine for treatment of lymphatic filariasis

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced today that it has signed a statement of intent with the World Health Organization to supply free of charge a primary medicine for the treatment of lymphatic filariasis.

19 Nov 2010

Call for more transparency and improvements to drug safety in Canada

A commissioned discussion paper released today by the Health Council of Canada, Keeping an Eye on Prescription Drugs, Keeping Canadians Safe, underscores the many limitations to how drug safety and effectiveness is monitored and reported in Canada. The report provides clear recommendations for changes to the current system to ensure Canadians are safe from undue pharmaceutical harm.

18 Nov 2010

Multiple epidemiological parameters drive increase in drug-treatment opportunities for pancreatic cancer: Decision Resources

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds significant trends in multiple epidemiological parameters to be driving the increase in drug-treatment opportunities for pancreatic cancer over the period 2009 to 2024, including population aging, increasing risk of recurrence following resection and modest improvements in survival.

18 Nov 2010

PAREXEL reaches milestone in early phase studies

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it reached a milestone of completing 200 early phase studies in patient populations during the past three years.

From Parexel 18 Nov 2010

CDC data: Adults remain unvaccinated against preventable infectious illnesses

New data from the Centers for Disease Control and Prevention (CDC) show that adults remain largely unvaccinated against preventable infectious illnesses.

18 Nov 2010

Multiple sclerosis drug shows promise to counteract effects of botulinum neurotoxin

Scientists are reporting that variants of a drug already approved for treating multiple sclerosis show promise as a long sought treatment for victims of bioterrorist attack with botulinum neurotoxin which is 10,000 times deadlier than cyanide and the most poisonous substance known to man.

18 Nov 2010

FIP's PSWC and AAPS Annual Meeting to highlight targeted inhalable dry powder HPV vaccine

New research being presented at the 2010 FIP Pharmaceutical Sciences World Congress in association with the American Association of Pharmaceutical Scientists Annual Meeting and Exposition will highlight a targeted inhalable dry powder vaccine that may prove preferable in terms of needle avoidance and expected lower cost than the current commercial human papillomavirus (HPV) vaccine used throughout the world.

18 Nov 2010

Pharmaceutical News

Personalised medicine could help develop effective treatments for serious diseases

Doctors recommend drug holidays from bisphosphonates to enhance bone health

Jeffrey Bethune files lawsuit against Bristol-Myers Squibb for denying overtime pay

National monitoring essential for preventing emergence of malaria drug resistance

Advanced Life Sciences submits application to FDA for ALS-886 to treat ARDS

Ethicon submits BLA to FDA for Fibrin Pad

FDA approves IDE application for Home Hemodialysis system

FDA approves new drug application for NEXTERONE Premixed Injection

Expert panel to endorse newly approved therapeutic vaccine for advanced prostate cancer

New findings show promising treatment for MS

Eisai signs statement of intent with WHO to supply medicine for treatment of lymphatic filariasis

Call for more transparency and improvements to drug safety in Canada

Multiple epidemiological parameters drive increase in drug-treatment opportunities for pancreatic cancer: Decision Resources

PAREXEL reaches milestone in early phase studies

CDC data: Adults remain unvaccinated against preventable infectious illnesses

Multiple sclerosis drug shows promise to counteract effects of botulinum neurotoxin

FIP's PSWC and AAPS Annual Meeting to highlight targeted inhalable dry powder HPV vaccine

Sun Pharma receives FDA approval for generic Tiazac ANDA

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

FDA approves Sun Pharma's generic Clarinex ANDA

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News